The funds will be used to advance technology needed to support the production of sterile injectable medications. This includes current good manufacturing practice (cGMP) nonsterile and bulk manufacturing, aseptic fill and finish, labeling, and related services. The company also provides drug formulation, process design and scale-up, analytical and stability testing, and research services that feature target validation, characterization and assay development, protein engineering, and cell line development.

The series A extension was led by Polaris Partners.

FDA updates requirements for COVID-19 vaccine EUAs
The U.S. Food and Drug Administration (FDA) issued a new guidance document on May 25 that updates previously issued guidance and sets expectations for...

Ajinomoto expands fill-finish capacity
Ajinomoto Bio-Pharma Services is opening a high-speed, multipurpose fill-finish line in its commercial manufacturing facility located in San Diego, CA.

Report identifies 8 areas of growth in genetics/genomics industry
With a $265 billion contribution to the U.S. economy in 2019 alone, the human genetics and genomics industry is thriving and promises to have a major...